Waters Corporation (WAT)
Orchestra Biomed Holdings Inc (OBIO)
Bristol-Myers Squibb Company (BMY)
Bristol Myers Squibb’s Application for Breyanzi (lisocabtagene maraleucel) Accepted for Priority Review by U.S. Food and Drug Administration (FDA) in Fifth Cancer Type for Relapsed or Refractory Marginal Zone Lymphoma (MZL)
Bristol-Myers Squibb Co. (BMYMP)
Bristol Myers Squibb’s Application for Breyanzi (lisocabtagene maraleucel) Accepted for Priority Review by U.S. Food and Drug Administration (FDA) in Fifth Cancer Type for Relapsed or Refractory Marginal Zone Lymphoma (MZL)
BIORA THERAPEUTCS INC (BIOR)
Twist Bioscience (TWST)
Select Medical Holdings (SEM)
CRISPR Therapeutics (CRSP)
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
CVRx Inc. (CVRX)
New Form 8-K - CVRx, Inc. Filed: 2025-08-04 AccNo: 0001104659-25-073638 Size: 294 KB Item 2.02: Results of Operations and Financial Condition Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits
Fortrea Holdings Inc (FTRE)
Semler Scientific Inc (SMLR)
agilon health Inc (AGL)
New Form 8-K - agilon health, inc. Filed: 2025-08-04 AccNo: 0001628280-25-037426 Size: 2 MB Item 2.02: Results of Operations and Financial Condition Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 5.03: Amendments to Articles of Incorporation or …
Indivior PLC (INDV)
SI-BONE Inc. (SIBN)
New Form 8-K - SI-BONE, Inc. Filed: 2025-08-04 AccNo: 0001459839-25-000073 Size: 332 KB Item 2.02: Results of Operations and Financial Condition Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits